Oppenheimer Initiates Coverage On Spruce Biosciences with Outperform Rating, Announces Price Target of $283

Benzinga · 2d ago
Oppenheimer analyst Leland Gershell initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Outperform rating and announces Price Target of $283.